Stock Analysis of Codiak BioSciences Inc (CDAK)

Loading ...

Birds Eye View of Codiak BioSciences Inc

Birds's Eye

Technical Analysis of Codiak BioSciences Inc

Stock Analysis of Codiak BioSciences Inc (CDAK) - Birds Eye View

1W 2W 1M 3M 1Y 2Y 5Y

Overview

Code	CDAK
Close	0.0216
Change	0.0016 / 8.00 %
Volume	650226
Vol Change	-1223.43 K / 65.30 %
Industry	Biotechnology
Sector	Healthcare

AIO Strength Index

Technical Strength	Bearish
Growth Index	Mild Growth
Value Index	Mild Value
Profitability Index	Poor Profitability Stock
Stability Index	Very Low Stability Stock

Fundamental View of Codiak BioSciences Inc

PE (TTM)

-0.0127

Very Poor

Price / Book

0.0114

Excellent

Price / Sales

0.0248

Excellent

Piotroski F Score

3.0

Not Good

Market Cap

795519

Enterprise Value

-48051.48 K

All Financial Ratio's

ROA (TTM)

-26.24

Very Poor

ROE (TTM)

-89.47

Very Poor

Net Margin (TTM)

-195.01

Very Poor

Revenue

686.79 %

22935.00 K

Net Profit

59.46 %

-37157.00 K

Debt to Equity

0.525

Good

Altman Z Score

-2.96

Very Poor

Quick Ratio

3.37

Very Good

Cash Ratio

2.83

Good

Financial Statement Analysis

Highs/Lows of Codiak BioSciences Inc

Period	Old price	Stock Return	S&P 500 Returns	High	Low	High Date	Low Date
One Week	0.0238	9.24 %	0.513 %	0.035	0.017	11-Apr-23	12-Apr-23
Two Week	0.19	88.63 %	0.486 %	0.199	0.017	31-Mar-23	12-Apr-23
One Month	0.5086	95.75 %	4.80 %	0.62	0.017	17-Mar-23	12-Apr-23
Three Month	0.602	96.41 %	3.56 %	0.938	0.017	03-Feb-23	12-Apr-23
Six Months	0.66	96.73 %	15.54 %	0.96	0.017	02-Nov-22	12-Apr-23
One year	4.41	99.51 %	26.26 %	4.429	0.017	14-Apr-22	12-Apr-23
Two year	13.66	99.84 %	27.72 %	19.99	0.017	17-Sep-21	12-Apr-23

Technical View of Codiak BioSciences Inc

RSI

21.29

Mild Bullish

MACD

-0.136

Bearish

ADX

45.49

Bearish

Super Trend

0.161

Mild Bearish

Williams %R

-98.96

Mild Bullish

CCI

-81.87

Mild Bullish

Technical Analysis Deep Dive

EMA 5

0.0330

Mild Bearish

EMA 15

0.142

Mild Bearish

EMA 50

0.374

Strong Bearish

EMA 100

0.620

Strong Bearish

SMA 100

0.520

Strong Bearish

SMA 200

1.10

Strong Bearish

SMA 5 / 20

0.0218 / 0.237

Strong Bearish

SMA 15 / 50

0.145 / 0.456

Strong Bearish

SMA 50 / 200

0.456 / 1.10

Mild Bearish

MA Analysis Deep Dive

Charts of Codiak BioSciences Inc

Returns of Codiak BioSciences Inc with Peers

Period / Stock	CDAK	ACOR	TCDA	HSTO
1 Week	-9.24%	-60.65%	11.90%	1.18%
1 Mth	-95.75%	-94.49%	-22.10%	-50.86%
3 Mth	-96.41%	-95.96%	-89.71%	-45.40%
6mth	-96.73%	-93.85%	-99.85%	-49.41%
1 Year	-99.51%	-93.99%	-99.83%	-80.09%
2 Year	-99.84%	-98.01%	-99.73%	-94.96%
5 Years	-	-99.96%	-	-99.89%
charts	-

View All Together in Chart Inline Tile

Compare Fundamentals of Codiak BioSciences Inc with Peers

Ratio / Stock	CDAK	ACOR	TCDA	HSTO
PE	-0.0127	-0.0017	-0.0060	-42.84
P/B	0.0114	-0.0346	-0.0120	52.37
ROA	-26.24	-170.31	-98.22	-83.91
ROE	-89.47	0	0	-111.37
Debt To Equity	0.525	-0.0101	597.47	0
Revenue	22935.00 K 686.79 %	111118 K 6.28 %	0 %	19000.00 99.50 %
Net Income	-37157.00 K 59.46 %	-15951.00 K 75.80 %	-176566.00 K 33.32 %	-12377.00 K 11.41 %

Technicals of Codiak BioSciences Inc with Peers

Technical / Stock	CDAK	ACOR	TCDA	HSTO	-
ADX	45.49	39.16	36.04	31.21
CMF	-0.096	-0.438	-0.183	-0.138
MFI	13.85	0.925	59.72	24.79
RSI	21.29	17.04	29.14	36.04
MACD Abv Signal	False	False	True	True
Price Above 50 MA	False	False	False	False	-
Price Above 200 MA	False	False	False	False	-

About : Codiak BioSciences Inc

Address : 35 Cambridge Park Drive, Cambridge, MA, United States, 02140
Tel : 617 949 4100
URL : https://www.codiakbio.com
Code : CDAK, ISIN : US1920101060, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 14_Oct_2020
Employee Count : 102

Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics S.A.S., Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. On March 27, 2023, Codiak BioSciences, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Note : All Data Generated at the End of Trading Hours (EOD Data)